ready extensive armamentarium of antihypertensive drugs we examined the clinical, hemodynamic, renal, and metabolic changes that followed its use. The present report describes studies indicating that this antihypertensive agent provides special advantages because, while lowering arterial pressure, it also has relatively few side effects and does not compromise cardiac nor renal function.
Materials and Methods
Clinical Observations (25 Patients) Twelve nmen and 13 women on the medical wards of Los Angeles County Hospital were selected for the study. Each one of these patients had registered a diastolic pressure of 110 mm. Hg or higher after admission to the hospital. No drugs had been used for the treatment of hypertension for 2 weeks prior to our study. Basic study included complete history and physical examination, routine blood and urine tests, intravenous pyelography, measurements of urinary catecholamine excretion, measurements of plasma electrolyte concentration, and urine cultures. Pertinent diagnostic data are tabulated in table 1. Specific cause of hypertension was not found in 22 of the patients. In two patients hypertension was associated with chronic pyelonephritis, and in one with polycystic kidney disease.
Nine of the patients were treated with daily doses of 3.0 Gm. of the racemie mixture of alphamethyl DOPA (MK 350), while 16 received 1.5 to 3.0 Gm. of the levorotatory compound (MK 351). Only the levorotatory isomer is pharaiacologically active," so that 3.0 Gm. of MK 350 is equivalent to 1.5 Gm. of MK 351. The medication was administered orally, in equally divided doses, two or three times daily. The patients were observed for a control period of 5 days prior to administration of medication. Blood pressure was measured by standard clinical technies in the supine, sitting, and standing positions, four times daily. During the control period the diastolic blood pressure fell below 110 mm. Hg in only three patients. Observations were continued for approximately 10 
Toxicologic Survey
Plasma volume was measured in three patients Laboratory studies were performed on the last by the T-1824 dye methods: 10 mg. of dye were day of the control period, on the final day of treat-injected intravenously and samples of arterial ment, and between 5 and 13 days after discontinu-blood were oblained prior to injection and at 10, ance of medication. The determinations included 20, 30, and 60 minutes. The dilution factor was blood hemoglobin concentration, hematocrit, white calculated by logarithmic regression of dye conblood count, serum potassium, blood urea nitrogen, centration in plasma, to zero time, as described liver function tests, and routine 12-lead electro-by Noble and of at least two clearance periods. Central venous hematocrit was multiplied by 0.9 to obtain an estimate of body hematocrit for calculation of renal blood flow.
Metabolic Balance (2 Patients)
Two patients were observed on the Mletabolic Ward. Sodium intake was kept constant at 100 nlEq. per day (based on laboratory analysis of the diet) and base line observations were made for 7 days. Alpha-miiethyl DOPA was admninistered in amounts of 750 mg. twice daily for 10 days in one patient (S.R.) and for 6 days in the second patient (E.T.). Body weight and urinary excretion of sodium and potassium were measured daily; blood pressure was obtained in the supiine, sitting, and standinig postures aild recorded four timnes daily. Results
Clinical
After adminiistration of alpha-methyl DOPA the blood pressure fell in every patient, in the standing as well as in the supine posture. These changes were highly significant (p < .001). In the 5 days following cessation of mnedication a significant reduction of blood pressure persisted. Average values and statistical limits are shown in table 2. The six remaining patien-ts (and an additional group of eight patients niot detailed in this report) were mailntained on medication on an outpatient basis for a period exceeding 3 months. In all these cases the blood pressure had been nlaintained at a satisfactory low level.
The effective amount of the levorotatory compound-equivalent ranged from 1.5 to 2.5 Gm., administered in two or three divided doses daily; the one patient who received 3.0 Gm. had excessive postural hypotension.
A hypotensive effect usually was first manifest within eight hours after the oral dose. The peak effect occurred between 12 and 24 hours, but occasionally it was delayed for as long as 48 hours. Reduction of blood pressure proceeded gradually. Thus, when administered in adequate doses the drug appeared to "c normnalize" blood pressure. Excessive or unpredietable hypotensive effects were rarelv observed. Postural hypotension occasionally proved troublesome, but rarely so when the patients were forewarned. The drug was well tolerated and patient acceptance was good. The only side effect consistently observed was sedation to the extent that the patient preferred to remain in bed during the first 24 hours after treatment was begun. Sedative effects usually had subsided by the second day and only occasionally by the third day.
Toxicologic
The white blood count, fasting blood sugar, blood urea nitrogen, serum creatinine, total serum bilirubin, alkaline phosphatase, thymol turbidity, SGO-transaminase, and serum potassium were not significantly modified by the treatment.
The hemoglobin concentration fell in all but three cases. A 5-Gm. fall in two patients was associated with progressing uremia. In the case of one patient (O.P.) physical signs of jaundice without subjective discomfort were noted after 3 months of treatment. Unfortunately, the patient refused examination at that time and treatment was discontinued.
However, she returned 2 months later, well, and with normal liver function. Therapy was reinstituted and maintained for an additional 3 months. No ill effects have followed.
Hemodynamic
Results of hemodynamie studies are summarized in table 4. Only a slight decrease in Circulation, Volume XXVIII, August, 1963 the cardiac index occurred after blood pressure had been lowered. Venous pressure and mean eirculation time were slightly decreased. Peripheral vascular resistance was reduced during therapy with alpha-methyl DOPA. There was a concomitant reduction in stroke work. When the patients were tilted head-up 60 degrees, an additional fall in the arterial pressure was observed, but under this circumstance peripheral resistanee was not additionally reduced ( fig. 1) . A significant observation was an increase in plasma volume, which suggested that dilution was the factor responsible for the consistently lower hemoglobin and hematocrit readings. Reduction in arterial pressure during treatment with alpha-methyl DOPA accompanied by a corresponding decline in peripheral resistance.
Renal Function
Creatinine clearance inereased in six of nine patients. In only one instance was a definitive decrease shown. Clearance of paraaminohippurate was not significantly altered.
The findings therefore gave evidence that treatment with alpha-methyl DOPA does not reduce glomerular filtration rate but may result in inereased filtration fraction. Renal blood flow remained essentially unaltered (table 5). The average values and their relationship to arterial pressure, blood urea nitrogen, and serum creatinine concentration are showvn in figure 2.
Metabolic
Treatment was followed by a net retention of sodium and a gain in body weight (fig. 3 ). The weight gain, sodium retention, and reduction in blood pressure paralleled one another. No symptoms referable to sodium retention were noted in either of these patients. of moderate and severe hypertension. Administered in amounts varying from 0.5 to 3.0 Gm., it produces a predictable and sustained hypotensive effect. Its action has proved reliable within the framework of the present study, and it was well tolerated even in the presence of uremia and congestive heart failure. Indeed, it may be especially suitable for the treatment of patients with renal and cardiovascular complications. Agents that produce hypotension by ganglionic blockade (hexamethonium, pentolinium, mecamylamine) or blockinig of transmission of sympathetic impulses at the sympathetic neuro-effector site (guanethidine, bretylium) all reduce cardiac output, but the changes in peripheral resistance are quite variable. [21] [22] [23] [24] The hemodynamic effects of these agents are largely due to gravitational pooling of blood in the splanchnic venous and peripheral venous beds. Restall and Smirk25 demonstrated this mechanism bv showing that immersion of the body in water eanceled the effects of ganglionie blocking agents; Imhof et al. 26 prevented the orthostatic reduction of blood pressure by inflation of a "g" suit to pressures that overcame venous pooling of blood in the dependent parts of the body; and Bradley27 observed an increase in splanchnic blood volume following hexamethonium and pentolinium. The capacity of vascular bed is increased, the return of venous blood to the heart is correspondingly reduced, and diminution of cardiac output results. This lowering of cardiac output and consequent reduction in coronary blood flow are known to create special risks. In the presence of left ventricular hypertrophy and coronary atherosclerosis, characteristic complications of hypertension of long standing, additional compromise of an already inadequate coronary blood supply may be poorly tolerated. The clinician would prefer a drug that lowers blood pressure without subjecting the patient to the hazardous effects from venous pooling. This advantage is, in part, provided by alphamethyl DOPA. In the patients studied by us, the cardiac output was not significantlv altered. By comparison, we found that alphamethyl DOPA causes a drop in arterial pressure, primarily by decreasing peripheral resistance with little or no concomitant fall of cardiac output in the supine posture. This reduction in peripheral resistance is attributed to arteriolar dilatation and was of greater magnitude than has usually been observed by others during administration of ganglion-blocking agents.
Orthostatic effects indicate that additional hypotensive mechanisms not unlike those of ganglion-blocking drugs are also called into action. The exaggerated decline in arterial pressure without corresponding fall in peripheral resistance in the 60-degree head-up position suggests that gravitational effects result in venous pooling and decreased venous return. These features have been emphasized by Kirkendall and Wilson,28 who studied the acute hemodynamic effects of a single intravenous dose of alpha-methyl DOPA in five hypertensive patients.
The mechanism of action of alpha-methyl DOPA as a hypotensive agent is still obscure. Sodium diuresis is not a factor. On a control intake two of our patients retained sodium and gained weight. The hypotensive effect Circulation, Volume XXVIII, August, 1963 does not temporally correspond to the period when DOPA decarboxylase inhibition occurs. Hess, Connamacher, Ozaki, and Udenfriend29 have shown that tissue levels of norepinephrine in brain and heart fall quite rapidly after administration of alpha-methyl DOPA to rats and guinea pigs. Enzymatic inhibition wears off within 18 hours, but norepinephrine levels remain depressed for several days. Furthermore, they showed that alpha-methylmeta-tyrosine, a closely related analog, altered the ability of heart tissue to take up or to hold norepinephrine, an effect not unlike reserpine. The findings of Cannon et al.8 in man that vanillylmandelic acid excretion, a major norepinephrine metabolite, is unaltered by alpha-methyl DOPA further supports the view that norepinephrine biosynthesis is intact.
From a clinical viewpoint, it is reassuring that alpha-methyl DOPA did not cause a decrease in renal blood flow or glomerular filtration rate. To the contrary, glomerular filtration rate was increased in six of nine patients studied. No significant elevation of the blood urea nitrogen occurred except in two patients in whom renal failure progressed rapidly in spite of therapy. Therefore this agent might prove particularly helpful in the treatment of patients with malignant hypertension and renal failure. Our findings concur with those of Cannon et al.,8 who reported favorable effects in patients with malignant hypertension and renal failure and found no decrease in sodium para-aminohippurate or inulin clearance after effective reduction of arterial pressure with alpha-methyl DOPA.
In addition to its antihypertensive action, alpha-methyl DOPA has a subtle tranquilizing, and often a mood-lifting, effect that is favored by patients. No tolerance to its antihypertensive action has been observed. Its over-all effectiveness as an antihypertensive agent, based on an experience with almost 1,500 patients collected by Foltz30 has been 65 per cent. In the present study, in which generally higher doses were used, the agent was effective in 90 per cent, and in Cannon's 12EIL W BARBOUR, CHESNE series8 in 94 per cent of patients studied. When used in conjunction with the thiazides an added hypotensive effect is obtained.9 ' 31 The most hopeful feature of alpha-methyl DOPA is the abseniee of troublesome side effects. Drowsiness has been the most frequent side effect. It persists usually for 24 hours but occasionally as long as 72 hours, it is closely related to the amount adminilistered, and recurs on increase of the dose. Postural hypotension, although consistently observed, has rarely been a symptomatic problem after stabilization of the dose. The only gastrointestinal symnptoms observed were mild dryness of the nmouth and transient diarrhea, which occurred in one patient.
No hepatic toxicity has been demonstrated in this series. In the series of approximately 1,500 patients collected by Foltz, however, abnormalities of liver chemistry were observed in 11 patients of whom five also were observed to have fever. There was no other clinical evidence of liver damage. Both the fever and the abnormalities of the liver function tests subsided after the drug was discontinued. Fifteen patients had fever without hepatic abnormalities, which subsided after discontinuation of the drug."' 30 In one of our patients (O.P.) there was an uncertain relationship between the use of the drug and development of jaundice, which, however, did not reappear after re-institution of therapy. Granulocytopenia, which was rapidly reversed when therapy was stopped, has been reported in one patient by Hallwright32 from New Zealand. A reduction of hemoglobin and red cell count in some patients is best explained by plasma dilution, which was observed in our series.
We would regard alpha-methyl DOPA sufficiently free from toxic effects to justify its clinical use, but we recognize the total nuniber of patients studied to date is sufficienitlv small that more definitive reassurance is premature.
If the safety of the drug is confirmed by observations in a larger number of patients, alpha-methyl DOPA is likely to achieve an important place in the antihypertensive armamentarium. In mildness of side effects it probably ranks with reserpine-thiazide combinations, but outranks them in terms of potency. In terms of potency it is outranked by guanethidine and mecamylamine. It may well replace hydralazine which, although it has favorable effects on renal funetion, is less potent in its antihypertensive action and also is beset by a high incidenee of intolerable side effects. 33 Therapy with alpha-methyl DOPA may be started with 250-mg. tablets or capsules administered in the morning and evening, and gradually increased until a favorable antihypertensive and symuptomatic response is obtained. In selected instances the effectiveness is auganented by the additioii of thiazide in amounts equivalent to those used in reserpine-thiazide combinations.
Summary and Conclusions
Alpha-methyl DOPA is a decarboxylase inhibitor that effectively lowers blood pressure. Twenty-five hypertensive patients were observed approximately 5 days prior to therapy, 10 days while receiving alpha-methyl DOPA, and 5 days after therapy. A satisfactory antihypertensive effect, accentuated in the upright posture, was observed in 22 patients. Side effects other than somnolence, which subsided after 24 to 72 hours, were negligible. Toxicologic evaluation failed to demonstrate unfavorable hepatic, renal, or heinatologic effects.
Hemodynamic studies in four patients showed that the fall in arterial pressure is principally due to a reduction in peripheral resistance, since cardiac output remained essentially unchanged in the supine posture. Renal blood flow and glomerular filtration rate, measured in 10 patients, were unaffected or increased. Metabolic balance studies deinonstrated that hypotensive effects were not associated with sodium diuresis; to the conitrary, mild sodium retention was observed in 2 patients.
Alpha-methyl DOPA is an effective antihypertensive agent, intermediate in potency Circulation, Volume XXVIII, August, 1963 between reserpine-thiazide combinations and ganglionic-sympathetic blocking drugs. Because it produces relatively few undesirable side effects, it is well accepted by patients. Its favorable actions on cardiac output and renal blood flow provide special advantages for the patient with advanced hypertension aggravated by cardiac or renal complications.
Medicine: A Universal Bond
Leaving aside the strengthening of the formation of a scientific and cultivated spirit, leaving aside the sustained effort of constant renewal of our intellectual baggage, a task which rests within ourselves and in our schools, there exists a factor which may come to our aid, and that is international cooperation. I understand it as a generous disposition of spirit, shared by all in our field across the length and breadth of the earth, to break down those national barriers which shelter selfishness and self sufficiency, if not suspicion; to open doors to outside ideas from whichever country they may come, demanding only that they be well founded; to cooperate in the projects of others, asking only that they be noble and of promise; to aid in the development of scientific schools which, being small or newly founded, ask for more help;
I understand it, that is to say, as an impulse of intellectual comprehension, of human sympathy, of universal awareness.
There is nothing better for the encouragement of such a movement than our Congresses. Years ago in our meeting in Washington. imbued with this idea, I stated that there was no profession like ours for learning the secret of living together and helping each other. "The truth is that we are," I said, "a group cast in the same mould. It matters little that the metal was cast in Europe or in Africa, in Asia or in America. It matters little that the metal is fair or dark. The mould is always the same, oecumenical and eternal. It is the legacy of our forefathers in Egypt and in Greece and it is in which, one day, our descendants will be cast." Going on I added, sustaining my assertion, "We who love medicine have been given by it a peculiar trait: we can never achieve possession of it and are indeed possessed by it as by a demon within us. Once it covers us it is like the tunic of Neso that could never be removed."-DR. IGNACIO CHAVEZ. Speech delivered at the Inaugural Ceremony of the IV World Congress of Cardiology. Universidad Nacional Autonoma de Mexico, Mexico, D.F., 1962, p. 9.
Circulation, Volume XXVIII, August, 1963 
